ArticleEpilepsia2025
Real-world retention of newer ASMs, including lacosamide and brivaracetam as first or second therapies in adult-onset epilepsy.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bistromathics in Epilepsy and the Relativity of Numbers.CNS drugs · 2026Article
- Review
- Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?Neurology and therapy · 2026Article
- Observational
- Physician Perspectives on Web-Based Real-World Statistics for Better-Informed Drug Selection in Epilepsy: Mixed Methods Study.JMIR formative research · 2026Article
- Real-world retention of newer ASMs, including lacosamide and brivaracetam as first or second therapies in adult-onset epilepsy.Epilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveNewer antiseizure medications (ASMs), such as lacosamide and brivaracetam, have promising retention in clinical trials but real-world data on their effectiveness when used as first or second treatments is missing. Because newer ASMs are often reserved for severe cases, such knowledge accumulates slowly. We utilized nationwide "big data" and aimed to evaluate real-world retention of these ASMs when used early in the disease course.
methodsWe used longitudinal national register data to identify all adults with incident ASM-treated epilepsy in Sweden from 2007-2021. ASMs were tracked up to 2023, with recurring dispensations indicating continued treatment. Retention rates were calculated using Kaplan-Meier for each ASM as the first, second, or subsequent use (third ASM or later) with stratification for age and sex. Adjusted Cox regression was used to verify the risk of lacosamide discontinuation in comparison to levetiracetam.
resultsWe followed 49 489 adults for a median of 5 years (Q1-Q3, 3-10). The 5-year retention rates (95% confidence interval [CI]) of lacosamide were 42% (32%-55%) as first ASM and 61% (55%-67%) as second ASM among individuals 18-49 year of age, and 61% (53%-71%) and 69% (64%-74%) among 50 years or older, respectively. Lacosamide retention was comparable to lamotrigine and levetiracetam, but higher as a second ASM in younger adults and in men. The 3-year retention rate of brivaracetam as the second ASM among adults ≥50 years was 77% (95% CI 68%-88%). First or second treatment with cenobamate, eslicarbazepine, or perampanel was rare. The likelihood of discontinuing lacosamide as first ASM did not differ significantly from levetiracetam in univariable or adjusted Cox modeling. SIGNIFICANCE: Lacosamide and brivaracetam have at least similar real-world retention as lamotrigine or levetiracetam when used early in adult-onset epilepsy. This widens the therapeutic arsenal and the possibility of tailored ASM selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.